Andrew M Patterson

US Patent:

8099768, Jan 17, 2012

Filed:

Sep 18, 2008

Appl. No.:

12/233377

Inventors:

Qingwen Cheng - Pleasanton CA, US
Ping Luo - Pleasanton CA, US
Andrew Patterson - San Jose CA, US
Rajeev Angal - San Jose CA, US

Assignee:

Oracle America, Inc. - Redwood City CA

International Classification:

H04L 29/00

US Classification:

726 8, 709229

Abstract:

A method for multi-protocol logout. The method includes receiving, by a first identity provider, a logout request from a user agent, wherein the first identity provider executes in a federation manager, and initiating a logout on a service provider associated with the first identity provider based on the logout request by the first identity provider. The method further includes identifying, by the federation manager, a plurality of identity providers associated with the user agent, wherein the plurality of identity providers communicate using heterogeneous federation protocols, and initiating, by the federation manager, a logout on each of the plurality of identity providers based on the logout request using the plurality of heterogeneous federation protocols. The method further includes initiating, by the plurality of identity providers, a logout of each service provider corresponding to the plurality of identity providers, identifying a status of each logout, and sending the status to the user agent.

US Patent:

8476451, Jul 2, 2013

Filed:

Jul 21, 2008

Appl. No.:

12/669364

Inventors:

Jonathan A. Ellman - Oakland CA, US
Andrew W. Patterson - Oakland CA, US
Hillary Peltier - Jeanette PA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/426
A61K 31/427
C07D 277/30
A01N 43/78

US Classification:

548200, 548201, 514365

Abstract:

The present invention provides novel tubulysin analogues, methods of making and methods of using such analogues and conjugates thereof. The compounds of the invention are highly potent cell-growth inhibitors have been developed that are smaller and considerably more stable than tubulysin D.

US Patent:

20110263650, Oct 27, 2011

Filed:

Jul 21, 2008

Appl. No.:

12/669672

Inventors:

Jonathan A. Ellman - Berkeley CA, US
Andrew W. Patterson - Berkeley CA, US
Hillary Peltier - Berkeley CA, US
Florenz Sasse - Braunschweig, DE

Assignee:

HELMHOLTZ-ZENTRUM FÜR INFEKTIONS-FORSCHUNG GMBH - Braunschweig

International Classification:

A61K 31/454
A61P 17/06
A61K 31/426
A61P 35/00
C07D 401/12
C07D 277/587

US Classification:

514326, 546209, 548201, 514365

Abstract:

The present invention provides novel tubulysin analogues, methods of making and methods of using such analogues and conjugates thereof. The essential features for the potent cytotoxicity of tubulysin D have been established for the first time by the synthesis and evaluation of a series of analogues. By identifying functionality that surprisingly is not necessary for activity, highly potent cell-growth inhibitors have been developed that are smaller and considerably more stable than tubulysin D.